GENE ONLINE|News &
Tecentriq
ESMO21: Latest Clinical Studies Answer Central Questions in the Treatment of Leading Cancers
2021-09-22
Genentech Seeks FDA’s Blessings after Adjuvant Tecentriq Shows Promising Result in Lung Cancer Patients
2021-03-23
Tempest Lands Big Pharma Partnership to Trial Combo Therapy Against “Hard-To-Treat” Liver Cancer
2021-03-05
Roche’s Tecentriq Bags Landmark FDA Approval as First-Line Monotherapy for Metastatic NSCLC
2020-05-20
Tecentriq/Arbaxane Combo Becomes the First FDA Approved Immunotherapy Regimen for Breast Cancer Treatment
2019-03-14
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
